bmn 250
Recombinant proteinexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2016 (NCT02754076)
Timeline
Indications
Studied for
Mechanism of action
- Alpha-N-acetylglucosaminidaseSupplementation
NAGLU supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- bmn 250
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03784287 | Phase 2 | Feb 19, 2018 | Biomarin |
| NCT02754076 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2016 | Biomarin |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biomarin | For profit | 2 | 2 | 1 | 2016 |
1 organizations
Page 1 / 1